ADMA Biologics Inc (OQ:ADMA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: C/O Adma Biologics
Inc., 465 State Route 17
Tel: N/A
IR: See website
Key People
Steven A. Elms
Chairman of the Board
Adam S. Grossman
President, Chief Executive Officer, Director
Jerrold B. Grossman
Vice Chairman of the Board
Brian Lenz
Chief Financial Officer, Executive Vice President
James Mond
Chief Scientific and Medical Officer
Business Overview
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
Financial Overview
For the nine months ended 30 September 2018, ADMA Biologics Inc revenues increased 20% to $12.9M. Net loss increased 55% to $47.7M. Revenues reflect ADMA Bio Manufacturing segment increase from $2.4M to $5.8M, Corporate segment remaining flat at $107K. Higher net loss reflects ADMA Bio Manufacturing segment loss increase from $13.7M to $32.9M, Plasma Collection Center segment loss increase of 100% to $3.2M.
Employees: 295 as of Dec 31, 2017
Reporting Currency: U.S. Dollars
Enterprise value: $187.20M as of Sep 30, 2018
Annual revenue (TTM): $24.93M as of Sep 30, 2018
EBITDA (TTM): -$49.41M as of Sep 30, 2018
Net annual income (TTM): -$60.69M as of Sep 30, 2018
Free cash flow (TTM): -$60.53M as of Sep 30, 2018
Net Debt Last Fiscal Year: $1.57M as of Sep 30, 2018
Shares outstanding: 46,351,243 as of Nov 5, 2018
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization